Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 5
2020 2
2021 7
2022 7
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for cancer ferhatoglu
Your search for Caner Ferhatoglu retrieved no results
Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer.
Dogan I, Karabulut S, Tastekin D, Ferhatoglu F, Paksoy N, Sakar B. Dogan I, et al. J Coll Physicians Surg Pak. 2022 Aug;32(8):1014-1019. doi: 10.29271/jcpsp.2022.08.1014. J Coll Physicians Surg Pak. 2022. PMID: 35932125
METHODOLOGY: The clinicopathological characteristic and treatment data of patients with HER2/neu-positive metastatic gastric cancer were recorded retrospectively. Kaplan-Meier analysis was performed to compare the chemotherapy regimens. ...Three or more metastatic sites an …
METHODOLOGY: The clinicopathological characteristic and treatment data of patients with HER2/neu-positive metastatic gastric cancer w …
Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients.
Dogan I, Aydin E, Khanmammadov N, Paksoy N, Ferhatoğlu F, Ak N, Emiroglu S, Ibis K, Onder S, Tukenmez M, Cabioglu N, Kucucuk S, Muslumanoğlu M, Ozmen V, Saip P, Igci A, Aydiner A. Dogan I, et al. J Cancer Res Clin Oncol. 2023 Nov;149(16):14833-14841. doi: 10.1007/s00432-023-05276-y. Epub 2023 Aug 18. J Cancer Res Clin Oncol. 2023. PMID: 37594533
BACKGROUND: We evaluated the outcomes, and risk factors for recurrence in patients with early stage node-negative breast cancer in this study. METHOD: Retrospective data analysis was done on patient treatment records from 1988 to 2018. ...Ten- and twenty-year recurrence-fr …
BACKGROUND: We evaluated the outcomes, and risk factors for recurrence in patients with early stage node-negative breast cancer in th …
Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience.
Tastekin D, Paksoy N, Dogan I, Ferhatoglu F, Khanmammadov N, Bozbey HU, Karabulut S. Tastekin D, et al. J Cancer Res Ther. 2023 Jan-Mar;19(2):253-258. doi: 10.4103/jcrt.jcrt_672_22. J Cancer Res Ther. 2023. PMID: 37006064 Free article.
OBJECTIVE: The median survival time for metastatic gastric cancer that has a poor prognosis is usually shorter than 1 year. The fluorouracil, oxaliplatin, and docetaxel (FLOT) regimen is observed to be effective in the neo-adjuvant treatment of gastric cancer. Howev …
OBJECTIVE: The median survival time for metastatic gastric cancer that has a poor prognosis is usually shorter than 1 year. The fluor …
EXPRESSION OF ALU REPEAT IN BLOOD PLASMA OF PATIENTS WITH BREAST CANCER DURING NEOADJUVANT CHEMOTHERAPY: AN EXPLORATORY STUDY.
Özgür E, Ferhatoglu F, Sen F, Saip P, Gezer U. Özgür E, et al. Exp Oncol. 2023 Jun 26;45(1):120-124. doi: 10.15407/exp-oncology.2023.01.120. Exp Oncol. 2023. PMID: 37417275
BACKGROUND: Locally advanced breast cancer (LABC) rates are unusually high in developing countries. There is a need for the identification of predictive biomarkers for the selection of patients who could benefit from neoadjuvant chemotherapy (NAC). AIM: As the expression o …
BACKGROUND: Locally advanced breast cancer (LABC) rates are unusually high in developing countries. There is a need for the identific …
Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study.
Cil I, Kucukarda A, Atcı MM, Secmeler S, Paksoy N, Ferhatoglu F, Ak N, Ayhan M, Tataroglu Ozyukseler D, Onder AH, Avci O, Oyman A, Okten IN, Gulturk I, Akagunduz B, Basoglu T, Cakir E, Hacibekiroglu I, Ozcelik M, Aydiner A. Cil I, et al. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739. Epub 2021 Aug 7. Tumori. 2022. PMID: 34365852
INTRODUCTION: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, clinical trials underrepresent patients 65 years of age, lea …
INTRODUCTION: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and its survival advantage has been shown in advanced human ep …
Efficacy of Neoadjuvant Chemotherapy in Lobular and Rare Subtypes of Breast Cancer.
Seber ES, Iriagac Y, Cavdar E, Karaboyun K, Avci O, Yolcu A, Gurdal SO, Oznur M, Ekinci F, Aytac A, Gulturk I, Yilmaz M, Sever N, Kapagan T, Ferhatoglu F, Kahvecioglu FA, Hacibekiroglu I. Seber ES, et al. J Coll Physicians Surg Pak. 2024 Jan;34(1):37-41. doi: 10.29271/jcpsp.2024.01.37. J Coll Physicians Surg Pak. 2024. PMID: 38185958
OBJECTIVE: To determine the predictive factors for the pathological complete response (pCR) in patients with non-ductal invasive breast cancer (ND-BC) receiving neoadjuvant chemotherapy. STUDY DESIGN: Observational study. ...Predictive markers for pCR varied depending on h …
OBJECTIVE: To determine the predictive factors for the pathological complete response (pCR) in patients with non-ductal invasive breast c …
Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience.
Bahçeci A, Paydaş S, Ak N, Ferhatoğlu F, Saip PM, Seydaoğlu G, Bilici M, Şimşek M, Tekin SB, Çalikuşu Z, Yavuz S, Şahin AB, Çubukçu E, Evrensel T, Değirmencioğlu S, Demiray AG, Yumuk PF, Alan Ö, Çikman Dİ, Demirelli FH, Köstek O, Gökyer A, Doğan M, Bal Ö, Çakar B, Gökmen E, Yamaç D, Korkmaz T, Aliyev A, Keskin Ö, Urvay S, Büyükşimşek M, Karadeniz C, Yildiz B, Çinkir HY, Demir H, Beypinar İ, Karaçin C, Eser K, Baykara M, Kiliçkap S, Okutur K, Bulut G, Alkan A, Arpaci E, Pilanci KN, Demir A, Işik D, Yildirim N. Bahçeci A, et al. Cancer Invest. 2021 Jul-Aug;39(6-7):473-481. doi: 10.1080/07357907.2021.1933011. Epub 2021 Jun 7. Cancer Invest. 2021. PMID: 34014777
AIM: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast cancer (mBC) in different lines of treatment. METHOD: Retrospective analysis of T-DM1 results of human epidermal growth factor receptor 2 (H …
AIM: The aim of this study is to evaluate the efficacy and toxicity of trastuzumab emtansine (T-DM1) in cases with metastatic breast canc …
Circulating lncRNA H19 may be a useful marker of response to neoadjuvant chemotherapy in breast cancer.
Özgür E, Ferhatoğlu F, Şen F, Saip P, Gezer U. Özgür E, et al. Cancer Biomark. 2020;27(1):11-17. doi: 10.3233/CBM-190085. Cancer Biomark. 2020. PMID: 31640083
BACKGROUND: Novel biomarkers are needed to predict the effectiveness of the treatment of presurgical neoadjuvant chemotherapy (NAC) in breast cancer (BC). OBJECTIVE: This is an exploratory study to assess the impact of 3 cancer-related long non-coding RNAs (lncRNAs) …
BACKGROUND: Novel biomarkers are needed to predict the effectiveness of the treatment of presurgical neoadjuvant chemotherapy (NAC) in breas …
Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center.
Khanmammadov NA, Paksoy N, Doğan İ, Ferhatoğlu F, Saip P, Aydiner A. Khanmammadov NA, et al. Medicine (Baltimore). 2023 Sep 29;102(39):e35383. doi: 10.1097/MD.0000000000035383. Medicine (Baltimore). 2023. PMID: 37773844 Free PMC article.
Therefore, we investigated the efficacy and safety of systemic treatment in patients with IKS at our tertiary cancer center. This cross-sectional retrospective study analyzed the clinical data of 22 patients diagnosed with IKS between January 2000 and January 2020. ...
Therefore, we investigated the efficacy and safety of systemic treatment in patients with IKS at our tertiary cancer center. This cro …
30 results